Fetal exposure to environmental endocrine disruptors (EDs) is thought to contribute to reported idiopathic increases in adult male reproductive abnormalities. Although humans are exposed to myriad EDs from conception to adulthood, few studies have evaluated the effects of combined EDs on male reproduction. In the present study, we demonstrate that simultaneous gestational exposure to the phytoestrogen genistein and the antiandrogenic plasticizer di-(2-ethyhexyl) phthalate (DEHP) induces long-term alterations in testis development and function. Pregnant Sprague Dawley rats were gavaged from Gestational Day 14 to birth with corn oil, genistein, DEHP, or their mixture at 10 mg/kg/day, a dose selected from previous dose-response studies using single chemicals for its lack of long-term testicular effects. Hormonal and testicular end points were examined in adult male offspring. Serum testosterone levels were unchanged. However, significant increases were observed in testis weight and in the expression of mast cell markers in testes from adult rats exposed gestationally to combined compounds. The ED mixture also altered the mRNA expression of Sertoli cell makers Wt1 and Amh and germ cell markers cKit and Sox17, measured by quantitative real-time PCR (qPCR), suggesting long-term disruption in testis function and spermatogenesis. Alterations in germ cell markers might reflect direct effects on fetal gonocytes or indirect effects via primary targeting of somatic cells, as suggested by differentially regulated Leydig cell associated genes (Hsd3b, Anxa1, Foxa3, and Pdgfra), determined by gene expression array, qPCR, and protein analyses. The two chemicals, when given in combination, induced long-term reproductive toxicity at doses not previously reported to produce any conspicuous long-term effects. Our study therefore highlights a need for a more comprehensive evaluation of the effects of ED mixtures.
INTRODUCTION
Reported increases in the incidence of male reproductive abnormalities are believed to result from endocrine disruptor (ED)-induced perturbations of fetal programming and gonadal development [1] [2] [3] . Indeed, from the time of conception through adulthood, humans are exposed to countless anthropogenic and naturally occurring EDs. The androgen dependence and requirement of an adequate androgen/estrogen balance of the male reproductive tract creates a particular vulnerability to EDs possessing antiandrogenic or estrogenic properties [4] [5] [6] . Interestingly, several common environmental pollutants, including natural phytoestrogens, derivatives of plastics, paints, pesticides, and other industrial processing chemicals, have been shown to act as EDs and have been found in amniotic fluid, cord blood, breast milk, and semen [7] [8] [9] [10] [11] [12] .
The fetal period is a particularly sensitive and critical developmental window for the male reproductive system. Germ cell development is a highly controlled process that is regulated by a combination of endocrine and paracrine signals [13] [14] [15] [16] . During development, fetal primordial germ cells (PGCs) first migrate to the genital ridge and interact with somatic cells of the seminiferous cords and interstitium of the gonad primordia [17] . At this point, fetal germ cells are termed gonocytes [18] . While PGCs undergo erasure of their parental DNA methylation profile, the period of fetal to neonatal gonocyte development corresponds to active DNA remethylation and establishment of new paternal imprints [19] . Interstitial fetal Leydig cells produce testosterone necessary for differentiation of the urogenital tract and testis descent. Testosterone diffuses into the seminiferous tubules and, along with pituitary follicle-stimulating hormone (FSH), interacts with Sertoli cells. Sertoli cells provide factors that fuel germ cell metabolism and male reproductive development [20] .
Neonatal gonocytes proliferate and differentiate to form a critical pool of renewable spermatogonial stem cells (SSCs) that will support spermatogenesis. During spermatogenesis, testicular germs cells are transformed from round cells to cells with a unique shape, highly condensed nucleus, and flagellar apparatus. The generation of spermatozoa from stem cells allows the passage of genetic material to offspring. Therefore, improper SSC formation and differentiation carries the risk of generating spermatozoa that could transfer an altered genome or epigenome to the next generation.
Genistein is a plant derived phytoestrogen reported to have broad biochemical interactions, including estrogen receptor and peroxisome proliferator-activated receptor (PPAR) activation, direct or indirect antioxidant action, and modulation of important signaling molecules and DNA methylation [21] [22] [23] . Fetal exposure to genistein is predominantly via maternal ingestion of soy-derived products and subsequent placental transfer, whereas neonatal exposure is highest in soy formula fed newborns [10] . Fetal genistein exposure impairs testosterone production via ERa, inducing aberrations in prepubertal spermatogenesis and Leydig and Sertoli cell development and function [24] . Fetal exposure has also been shown to transiently alter intracellular signaling (PGDFRs, RAF1, MAPK) in neonatal gonocytes and affect neonatal and prepubertal spermatogenesis [25] [26] [27] .
Phthalates are plasticizing agents commonly used in the production of industrial and commercial products. They are used primarily in the production of polyvinyl chloride plastics [28] . DEHP is the most common phthalate plasticizer, accounting for over 50% of market share in 2010 [29] . DEHP is not chemically bound to plastic and can therefore leach out into the environment and contact humans. Fetal exposure occurs via maternal ingestion, inhalation, or dermal exposure. Neonatal exposure continues via contaminated breast milk, baby food, and water but is highest in neonates undergoing medical intervention using high-phthalate equipment [7-9, 11, 12] . Phthalates are well-known reproductive toxicants with androgen receptor-independent antiandrogen effects [30] . Fetal exposure to DEHP suppresses fetal and adult testosterone biosynthesis [31, 32] . Dose-dependent induction of testicular atrophy, alterations in Leydig and Sertoli cell numbers and functions, changes in sperm concentrations and motility parameters, and loss of spermatogenic cells types have been reported in numerous animal models for fetal phthalate exposure [33, 34] . DEHP or its principal bioactive metabolite, MEHP, has also been demonstrated to activate PPARs and alter DNA methylation status and estradiol-regulated proteins [35] [36] [37] [38] .
Relatively few studies have evaluated the effects of combined exposures [39, 40] , while animal studies often used doses exceeding environmental levels. We hypothesized that prenatal exposure to combined genistein and DEHP, at doses not previously reported to induce any conspicuous long-term male reproductive toxicity, will pose a greater risk than individual compounds.
We report herein that two common EDs induced long-term alterations in testis function and development in a manner that is different from individual compounds. Thus, the present findings indicate that assessing reproductive risk based on single chemical effects might not faithfully represent the true risks of exposure to ED mixtures during critical periods of male reproductive development.
MATERIALS AND METHODS

Treatments and Tissue Collection
Pregnant Sprague Dawley rats were purchased from Charles River Laboratories and kept on a 12L:12D photoperiod with ad libitum access to food and water. To address long-term alterations in testis development and function, pregnant rats were treated daily from Gestational Day 14 to parturition by gavage with 1 ml of corn oil alone (control) or containing genistein, DEHP, or a combination of genistein and DEHP, both used at a dose of 10 mg/kg (all from Sigma Aldrich, St. Louis, MO). This dose was selected from previous dose-response studies in which we had examined the short-and long-term effects of in utero exposure to genistein or DEHP used separately [25-27, 31, 32] . These studies had shown that a fetal exposure to 10 mg/kg/day genistein did not induce changes in circulating testosterone or germ cell numbers in adult rats [25] , while long-term effects of DEHP were seen for much higher doses [31, 32] .
The selected doses of genistein and DEHP correspond to 1.6-2.0 mg/kg/ day in human equivalents [41] . Equivalent doses were calculated with the formula human equivalent dose (in mg/kg) ¼ rat dose (in mg/kg) 3 (rat K m / human K m ), using human adult or child K m and rat K m , determined from the body surface area of both species [41] . Under normal conditions, human exposure to genistein and DEHP ranges from 0.01 to 0.2 mg/kg/day and from 0.003 to 0.03 mg/kg/day, respectively. Neonates fed soy-based infant formula or undergoing medical intervention, however, can experience levels that are 10-to 100-fold higher than the general population [8, 10, [42] [43] [44] [45] [46] .
Treatment doses were adjusted according to changes in dam weights. Gestationally treated male offspring were raised on a normal diet to defined adult ages, sacrificed, and analyzed. Male offspring were euthanized at Postnatal Day (PND) 60, 120, and 180 by CO 2 and weighed. Each end point was determined using randomly selected offspring of three to seven dams per treatment, where N is defined as the number of dams. In Figure 1 , N were 7, 4, 4, and 6 for controls, genistein, DEHP, and genistein þ DEHP-treated rats, respectively, at PND 120 and 5, 4, 3, and 5 at PND 180. Following the same order of treatments, in Figures 2-4 , N were 6, 4, 3, and 5, and in Figure 6 , they were 5, 4, 3, and 5, respectively. Testes were collected, weighed, and either snap frozen or fixed in paraformaldehyde. Blood of male offspring was collected by percutaneous cardiac puncture. Serum testosterone and luteinizing hormone (LH)/FSH were measured by radioimmunoassay and ELISA, respectively (data not shown). Animals were handled according to protocols approved by the McGill University Animal Care and Use Committee.
RNA Extraction and Quantitative Real-Time PCR
Testis RNA was extracted using QIAGEN RNeasy Plus Mini kit (Qiagen, Santa Clarita, CA). The cDNA was synthesized from isolated RNA using the single-strand cDNA transcriptor synthesis kit (Roche Diagnostics, Laval, QC). Quantitative real-time PCR (qPCR) was performed as previously described using the LightCycler 480 Real-Time PCR System (LC480; Roche Diagnostics) [47] . Alpha tubulin was used as an endogenous control and for normalization of gene targets. A minimum of three male offspring from different litters were evaluated in triplicate. The comparative Ct method was used to calculate relative expression. Data are represented as mean relative mRNA expression in arbitrary units. Complete primer sequences for all gene targets can be found in Table 1 .
Immunohistochemistry
Testis from male offspring were fixed in 4% paraformaldehyde and embedded in paraffin. Sections (4 lm) were used for immunohistochemical analysis as previously described [25] . Briefly, tissue sections were dewaxed and rehydrated, followed by antigen retrieval using a DAKO solution. Primary antibodies, PDGFRa (Abcam, ab61219) and HSD3b (Abcam, ab65156), were incubated at 1/100 and 1/300 dilutions, respectively, overnight at 48C and revealed using species appropriate secondary antibodies (mouse or rabbit), HRP/colorimetric HRP chromogen (AEC), and hematoxylin counterstaining. Representative images are shown.
Gene Expression Array Analysis
Ultrapure total RNA was extracted as described above from the testes of PND 120 rats, using offspring from three different dams per treatment, and diluted to 100 ng/ll following nanodrop analysis. Affymetrix 2.0 ST microarray analysis was conducted by Genome Quebec. Initial data analysis was performed by Dr. Jaroslav Novak as previously described [47, 48] . Briefly, data analysis contained quality control analysis, normalization, abbreviation and dispersion analysis, differential analysis of gene expression, and gene set enrichment analysis. Data were normalized using PLIER and further filtered using FlexArray, retaining only entries whose fold changes were greater than 40% relative to control and P-values were less than 0.05 according to the Bayesian approach and that were linked to a specific RefSeq. Pathway analysis (DAVIDS, Inginuity, and Reactome) and key word searches in PubMed were used to identify candidate genes for subsequent validation and expression studies.
Statistical Analysis
Excluding microarray data, all statistical analysis was performed using unpaired two-tailed t-test with statistical analysis functions in GraphPad Prism version 5.0 software (GraphPad Inc., San Diego, CA). Asterisks indicate a significant change relative to control (P 0.05, n varying from 3 to 7 per condition/end point).
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RESULTS
In Utero Exposure to Genistein and DEHP Alters Adult Testis Weights and the Expression of Inflammatory Mast Cell Markers
Examination of the body weights ( Fig. 1 , A and C) and anogenital distances (data not shown) of PND 120 and PND 180 male offspring revealed no significant differences between control and treated animals. At PND 120, however, the testis weights were significantly increased in the combined genistein and DEHP treatment group (Fig. 1B) , while there was an increasing trend for the same exposure at PND 180 (Fig. 1D ). Serum testosterone in PND60, PND 120, and PND 180, as well as PND 60 and PND 120 LH and FSH levels, were not altered following in utero treatments (data not shown).
The qPCR analysis of PND 120 testes showed an increase in the expression of inflammatory mast cell markers Cd13 ( Fig.  2A) , Cd33 (Fig. 2B ), and Cd38 (Fig. 2C ), observed only in the testis of PND 120 animals treated with combined genistein and DEHP. The mRNA expression of the proinflammatory macrophage marker Cd68 (Fig. 2D ) and anti-inflammatory macrophage marker Cd163 (Fig. 2E ) demonstrated an increased trend in the combined exposure group, but the changes were not statistically significant. Extracellular matrix markers collagen I, IV, and XVIII and laminin and fibronectin mRNA levels in testes were also quantified by qPCR but were unaltered in any treatment group relative to control (data not shown). 
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FIG. 2. Effects of in utero exposure to genistein and DEHP on testicular mast cells and macrophages. Relative mRNA expression of correlated mast cell markers Cd13 (A), Cd33 (B), and Cd38 (C) and macrophage markers Cd68 (D) and Cd163 (E) in PND 120 testis. Data are expressed as mean relative mRNA levels 6 SEM normalized to alpha-tubulin (n ¼ 3-6 per treatment). Asterisks indicate a significant difference relative to control (CTRL; P 0.05).
FIG. 3.
Effects of in utero exposure to genistein and DEHP on Leydig, Sertoli, and myoid cells. Relative mRNA expression of Leydig cell markers Cyp11a1 (A) and Tspo (B), Sertoli cell markers Amh (C) and Wt1 (D), and Leydig/Sertoli/myoid expressed Ar (E) and Esr1 (primarily Leydig; F) in PND 120 testis. Data are expressed as mean relative mRNA levels 6 SEM normalized to alpha-tubulin (n ¼ 3-6 per treatment). Asterisks indicate a significant difference relative to control (CTRL; P 0.05).
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FIG. 4. Effects of in utero exposure to genistein and DEHP on adult germ cells. Relative mRNA expression of SSC/undifferentiated spermatogonia marker Thy1 (A), differentiating spermatogonial markers cKit (B) and Sohlh2 (C), spermatogonia/pachytene marker Sox17 (D), zygotene marker Scp1 (E), and round spermatid marker Sp10 (F) in PND 120 testis. Data are expressed as mean relative mRNA levels 6 SEM normalized to alpha-tubulin (n ¼ 3-6 per treatment). Asterisks indicate a significant difference relative to control (CTRL; P 0.05).
In Utero Exposure to Genistein and DEHP Alters Adult Testis Expression of Key Somatic and Germ Cell Markers
The mRNA expression of known Leydig and Sertoli cell markers was examined by qPCR to gain insight into adult testis somatic cell function following in utero exposure to genistein and DEHP. Two Leydig-specific genes were initially examined: Cyp11a1, a gene that catalyzes the initial conversion of cholesterol to pregnenolone, and Tspo, a gene involved in cholesterol transport from the outer to the inner mitrochondrial membranes of steroidogenic Leydig cells [49] . While Cyp11a1 expression was not altered in any treatment group (Fig. 3A) , Tspo expression was significantly decreased in PND 120 DEHP-treated rats but not by genistein or combined genistein and DEHP (Fig. 3B) . Sertoli cell expressed Amh (Fig. 3C) and Wt1 (Fig. 3D) were significantly decreased only in genistein þ DEHP-treated animals, whereas Abp was not altered by any treatment (data not shown). The mRNA expression of two key steroid receptors, Ar and Esr1, was also determined. Ar was significantly increased in PND 120 animals treated with either genistein or genistein þ DEHP but not DEHP alone (Fig. 3E) . Esr1 was significantly decreased only in animals treated gestationally with the combined compounds (Fig. 3F) .
The expression of cell-specific germ cell markers [16, 50] was investigated to assess long-term effects on spermatogenesis. The SSC/undifferentiated spermatogonia marker Thy1 (Fig. 4A ) was decreased in DEHP and the combined treatment group, whereas differentiating spermatogonia marker cKit (Fig.  4B ) was significantly decreased only in the combined treatment group. Sohlh2, a spermatogonial marker enriched in undifferentiated spermatogonia, was significantly increased in all treatment groups relative to control (Fig. 4C) , whereas a late spermatogonia/pachytene marker, Sox17, was significantly decreased only in animals treated with both genistein and DEHP (Fig. 4D) . Finally, Scp1 (Fig. 4E) , expressed in zygotene, and Sp10 (Fig. 4F) , expressed in round spermatids, were not significantly altered in any treatment group.
Gene Expression Arrays Reveal Key Underlying Genetic Alterations in PND 120 Testis Following In Utero Exposure to Genistein and DEHP
Gene expression array analysis of PND 120 testes was conducted to mine underlying genetic aberrations following gestational exposure to genistein and DEHP. A combined total of 240 genes were significantly altered in all treatment groups FIG. 5. Effects of in utero exposure to genistein and DEHP on gene expression in adult testes. Affymetrix Rat Gene 2.0 ST MicroArray was performed on RNA extracts from the offspring of three dams per treatment and further used to mine significantly altered genes in PND 120 testis. Data were normalized in Affymetrix Expression Console using PLIER and further sorted using FlexArray. Venn diagrams represent the total number of significantly (!40% fold change; P 0.05) altered genes, up-regulated genes, and down-regulated genes relative to control. Values within individual circles represent the total number of gene changes within a particular treatment group relative to control. Numbers within shaded regions indicate the common gene changes between two specific treatment groups or all three (center).
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relative to control (Fig. 5 ). Animals treated with both genistein and DEHP had the greatest number of genes changes (90), followed by those treated with DEHP (88) and genistein (76) alone. Of the total 240 genes altered, 83 were up-regulated and 171 were down-regulated. Of note also is that there were a relatively low number of gene changes that were common between different treatments, emphasizing unique responses to individual or combined treatments.
Gene lists were sorted and blasted in PubMed to identify those implicated in male reproduction and development (Table  2) . Genes related to extracellular matrix (Dcn, Gsn, and Fn1) and intercellular communication (Gjb2 and Gjb6) were downand up-regulated, respectively, in various treatment groups, including combined genistein and DEHP. Of particular interest was the large number of Leydig cell-related genes (Pdgfra, Hsd3b, Lhcgr, and Stc1) that were found to be significantly altered in various treatment groups, while two novel Leydig candidate genes, Anxa1 and Foxa3, were significantly altered only in the combined treatment group.
Validation of Candidate Genes Identified by Expression Arrays
A subset of candidate genes identified by expression array analysis was further validated and examined by qPCR and IHC. Relative mRNA expression of Pdgfra was significantly 
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reduced in PND 120 testis of DEHP-and combined genistein and DEHP-treated animals (Fig. 6A) , whereas Hsd3b mRNA was significantly reduced in all treatment groups relative to control (Fig. 6B) . A novel candidate gene for endocrine disruption, Foxa3, was confirmed as being reduced only in response to the combined treatment (Fig. 6C) . Finally, consistent with expression array data, Stc1 mRNA levels were significantly reduced only in DEHP-treated animals relative to control (Fig. 6D) .
Immunohistochemistry was done on PND 120 testis tissue sections to investigate alterations in protein expression and localization. As previously reported in the literature, PDGFRa was expressed predominantly in interstitial Leydig cells (LC), blood vessels (BV), and myoid cells (MC) surrounding the seminiferous tubules in control PND 120 testis (Fig. 7A) . Consistent with qPCR and array results, interstitial localization of PDGFRa was slightly less intense in genistein-treated (Fig.  7B ) animals and considerably less in DEHP- (Fig. 7C) and combined genistein and DEHP-treated (Fig. 7D ) animals compared to control. The steroidogenic enzyme HSD3b was also expressed in the intersitium but was restricted to Leydig cells in control animals (Fig. 7E) . Also in agreement with qPCR and array data, there was substantially less HSD3b immunopositive staining in interstitial Leydig cells of genistein (Fig. 7F) , DEHP (Fig. 7G) , and combined genistein and DEHP-treated (Fig. 7H) animals.
DISCUSSION
The present study showed that combined exposure to two common EDs, genistein and DEHP, induced long-term alterations in testis function and development in a manner that 
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is different from individual compounds. A significant increase in testis weight and increases in mast cell markers Cd13, Cd33, and Cd38 mRNA were observed only in PND 120 testis animals treated gestationally with both compounds. CD13 is also expressed in granulocytes and monocytes and their precursors, as well as nonhematopoietic fibroblasts, whereas CD33 is expressed in myeloid progenitors, monocytes, granulocytes, and mast cells [51] [52] [53] . CD38-expressing mast cells are also found in close proximity to collagen-producing fibroblasts and are involved in the recruitment of inflammatory mediators [54] . Increases in mast cell and macrophage markers are hallmarks of inflammatory events in the testis, often associated with fibrosis [55, 56] . Indeed, exposure to both genistein and DEHP has been linked to such phenotype. High circulating levels of estrogen are linked to testicular fibrosis and mast cell infiltration, inflammation, and Leydig cell atrophy [57, 58] . The association with estrogen is also observable in mice overexpressing aromatase, which have increased testicular fibrosis, TNF-alpha signaling, mast cell and macrophage infiltration, and Leydig cell atrophy [59] [60] [61] . Neonatal exposure to DEHP also induced eosinophilic inflammation, mast cell degranulation, and eotaxin expression in humans, hallmarks of fibrosis in a rat air pouch model [62, 63] . Taken together, these findings indicate that combined in utero exposure to genistein and DEHP induce long-term alterations in proinflammatory testicular cells, creating a condition favorable to the development of fibrosis. The combined treatment altered the mRNA levels of the Sertoli cell makers Wt1 and Amh, suggesting long-term disruption in Sertoli cell function. Besides its role in gonad and seminiferous cord formation, WT1 has been shown to regulate PDGFa expression by Sertoli cells and to promote junctional complexes between Sertoli and germ cell, playing a critical role in spermatogenesis [64] . Although much of the literature has focused on the role of AMH in fetal and prepubertal periods, it is also expressed at significant levels in the adult testis and is dynamically regulated throughout spermatogenesis [65, 66] . Similarly, fetal exposure to the combination of genistein and DEHP led to reduced mRNA expression of several spermatogonial markers in adulthood, including Thy1, a glycoprotein highly expressed in SSC and early undifferentiated spermatogonia; the tyrosine kinase receptor cKit, a marker of differentiating spermatogonia; and Sox17, a transcription factor present at maximal levels in spermatogonia but also found in pachytene spermatocytes [67, 68] . Interestingly, the only significantly up-regulated germ cell marker, Sohlh2, is reported as being enriched in undifferentiated spermatogonia [69] . Together with recent studies highlighting the coexistence of SSCs and progenitor spermatogonia and the continuity between the successive steps of spermatogonial differentiation [70] , the present results suggest that fetal exposure to the combined EDs leads to the long-term disruption of spermatogonial genes and possibly altered kinetics of spermatogenesis.
Gene array analysis of in utero-exposed adult testes revealed underlying genetic alterations and insight into mechanisms of toxicity. The majority of altered genes were down-regulated and specific to a particular treatment group. Whereas some genes were uniquely affected by the ED combination, others showed exacerbated or normalized effects with the combination in comparison to single ED exposure, emphasizing the potential for additive, synergistic, or inhibitory effects when exposed to ED mixtures. The alterations in germ cell markers might reflect direct effects on fetal gonocytes or indirect effects via primary targeting of somatic cells, as suggested by the large number of Leydig cell-associated genes altered in the adult testis. Indeed, Hsd3b, Anxa1, Esr1, Foxa3, Pdgfra, and Stc1 mRNAs, as well as HSD3b and PDGRFa protein expression, were all significantly depressed in response to treatment. HSD3b catalyzes the synthesis of progesterone from pregnenolone, and decreased expression suggests a deregulation of a key steroidodogenic enzyme in the testis. Despite a significant reduction in HSD3b expression at the mRNA and protein level, global serum testosterone levels were not significantly altered in any treatment group. Further investigation is necessary to elucidate this discrepancy. A possibility is that circulating serum testosterone levels do not correlate with the elevated intratesticular levels observed in humans and rodents [71] . Indeed, rat intratesticular testosterone can be reduced by up to 60% while sustaining normal spermatogenesis [71] . Interestingly, Ar mRNA expression was significantly increased in genistein and combined treatment groups. Although a limited number of expression and conditional knockout studies have provided evidence for AR function in germ cells [72, 73] , in the adult, AR is expressed primarily in Leydig, Sertoli, and myoid cells [74] , where it plays a key role in androgen response. An increase in expression may therefore be a compensatory response to a decrease in intratesticular androgen levels and expression of Leydig cell-related genes.
Stc1, a calcium and phosphate-regulating glycoprotein hormone with demonstrated autocrine and paracrine functions in numerous mammalian tissues, was identified as a DEHPspecific target following in utero exposure [75] . Interestingly, Stc1 has been reported as having sexually dimorphic expression during embryonic and early postnatal development, appearing in interstitial mesenchymal cells as of Embryonic Day 12.5 and later in developing gonocytes in the seminiferous chords of the mouse testis [76] . Stc1 expression and testosterone production were also altered in isolated rat Leydig cells by exposure to the synthetic hormone dexamethasone and in early postnatal testis following gestational exposure to a known reproductive and development toxin, 2,3,7,8-tetrachlorodibenzo-pdioxin, suggesting an important role in both normal testis development and ED-mediated alterations [77, 78] .
Two novel candidate genes, Anxa1 and Foxa3, were depressed only in animals exposed to the combined treatment. ANXA1 is a Ca þ2 -dependent phospholipid-binding protein expressed in Leydig cells [79] . It is suggested to have antiinflammatory activity via phospholipase A2 inhibition, and therefore its reduction may also contribute to the observed inflammatory changes in adult testis [80] . FOXA3 is a testisspecific winged-helix transcription factor expressed in Leydig cells and postmeiotic germ cells [81] . Interestingly, complete knockout and haploinsufficient mice display germ cell loss and Sertoli cell only syndrome. Additionally, previously published microarray analysis of FOXA3 (À/À) mice identified subsequent gene alterations, including several interesting testisspecific Kallikreins implicated in semen liquifaction and male fertility [81] .
The effects on adult Leydig cells are particularly interesting when considering their origin; adult Leydig cells are derived not from fetal Leydig cells but rather from neonatal mesenchymal precursors [82, 83] . These results therefore suggest that there is a population of fetal cells that gives rise to the mesenchymal precursor of adult Leydig cells, either directly or indirectly disrupted in response to impaired fetal testis function. Indeed, the androgen sensitivity of adult Leydig precursors expressing chicken ovalbumin upstream promoter transcription factor II (Coup-tfII, NR2F2) [84] and AR was recently demonstrated in rodent ablation and regeneration model: fetal androgen deficiency, via AR knockout or dibutyl phthalate exposure, reduced adult Leydig stem numbers, resulting in compensated adult Leydig cell failure [85] . Interestingly, consistent epigenetic alterations were observed in both adult Leydig cells and fetal adult Leydig ''stem'' cells, suggesting a possible mechanism for impaired fetal Leydig programming. Studies involving platelet derived growth factor (PDGF) ligand and receptors (a/b) also reinforce this notion. PDGF is secreted by Sertoli cells and plays a key role in gonocyte proliferation and migration, fetal myoid cell migration and proliferation, and Leydig cell differentiation and proliferation [86, 87] . PDGFRa, which we have reported as being significantly depressed at the mRNA and protein levels in testicular interstitium, is expressed in both fetal and adult Leydig cells and their precursors, peritubular myoid cells, blood vessels, and gonocytes [26, 86, [88] [89] [90] . Interestingly, deletion of the PDGFa ligand (À/À) in mice results in few adult Leydig cells, reduced testis size and spermatogenesis arrest at PND 32, but normal fetal Leydig cells, again suggesting altered adult Leydig cell development via targeting of a distinct stemlike Leydig population [88] [89] [90] .
The present data suggest the ability of a combined fetal exposure of genistein and DEHP to induce long-term EFFECTS OF GENISTEIN AND DEHP ON MALE REPRODUCTION alterations in important somatic and germ cell markers in adult testis, supporting the notion of chemical susceptibility of this critical prenatal window. The alterations in germ cell markers might reflect direct effects on fetal gonocytes or indirect effects via primary targeting of somatic mesenchymal precursors present during the period of exposure, as suggested by the large number of Leydig-associated genes altered in the adult testis. A recent study reported cumulative effects of genistein and DEHP following gestational and lactational exposure, albeit at much higher doses not encountered in the environment and likely acting via different mechanisms of toxicity [91] . The doses used in our study, however, were not previously known to induce any conspicuous long-term reproductive toxicity in exposed animals. Moreover, these results suggest that in utero exposure to the combination of genistein and DEHP leads to long-term alterations in various testicular cell types. These changes could sensitize the testes to subsequent environmental insults by jeopardizing their ability to maintain homeostasis in response to stressors or by exacerbating inflammatory responses. Interestingly, consequences of EDs may also not be limited to F1 males, as epigenetic changes and subsequent gene alterations following fetal exposure have been demonstrated to persist until F3 via the paternal genome [92] [93] [94] . Thus, assessing reproductive risk based on single chemical effects might not faithfully represent the true risks of exposure to ED mixtures during critical periods of male reproductive development. We have identified several important candidate genes that will be the subject of further mechanistic studies. Future experiments will involve detailed analysis of early fetal and postnatal offspring of control and treated mothers. The aim of these studies will be to elucidate early cellular and molecular events contributing to long-term alterations in testis development and function. Of particular interest is investigating epigenetic aberrations, such as DNA methylation and histone modifications, that may be driving long-term perturbations in gene expression.
